2
Participants
Start Date
June 10, 2022
Primary Completion Date
March 27, 2024
Study Completion Date
March 27, 2024
Tocilizumab
Participants will receive intravenous (IV) tocilizumab
Klinika Za Djecje Bolesti Zagreb, Zagreb
"University Hospital for Infection Diseases Dr. Fran Mihaljevic - PPDS", Zagreb
Feinstein Institute for Medical Research, Manhasset
ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco, Lecco
Hospital Infantil Universitario Niño Jesus; Sección de Neuropediatria, Madrid
Hospital Universitario 12 De Octubre, Madrid
Hospital Universitario La Paz - PPDS, Madrid
CHRU Montpellier; SMPEA Peyre Plantade Centre de Ressources Autisme, Montpellier
Uniklinik Köln, Cologne
The University of Chicago, Chicago
Hospital Necker, Paris
Universitätsklinikum Ulm, Ulm
Reagan UCLA Medical Center, Los Angeles
Assistance Publique Hopitaux de Paris, Val-de-Marne
Central Michigan University College of Medicine, Mount Pleasant
University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital, Cleveland
UT Physicians - Pediatric Center - Texas Medical Center, Houston
University of Utah - PPDS, Salt Lake City
Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Hippokration Hospital, Thessaloniki
IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN, Rome
Szpital Kliniczny im Karola Jonschera Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu, Poznan
Global Clinical Trials Sunnyside, Pretoria
Hospital Sant Joan de Deu - PIN; Unitat de Recerca - Farmacia, Esplugues de Llobregat
Great North Childrens Hospital, Newcastle upon Tyne
Hoffmann-La Roche
INDUSTRY